Orogen Royalties Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 10K

Market Cap: -

Website: http://www.organon.com

Introduction: Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials

A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: ENG 120 µg + EE 15 µg intravaginal ring
Drug: DRSP 3 mg + EE 30 µg

First Posted Date: 2011-01-14

Last Posted Date: 2024-06-20

Lead Sponsor: Organon and Co

Target Recruit Count: 983

Registration Number: NCT01277211

A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Formoterol Fumarate DPI
Drug: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer
Drug: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer
Drug: Placebo MDI with spacer
Drug: Placebo MDI without spacer
Drug: Mometasone Furoate DPI

First Posted Date: 2010-12-13

Last Posted Date: 2024-05-23

Lead Sponsor: Organon and Co

Target Recruit Count: 92

Registration Number: NCT01258803

Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Asenapine

First Posted Date: 2010-11-19

Last Posted Date: 2024-05-28

Lead Sponsor: Organon and Co

Target Recruit Count: 157

Registration Number: NCT01244828

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Phase 3

Completed

Conditions: Bipolar Disorder, Pediatric

Interventions: Drug: Placebo to match asenapine
Drug: asenapine
Drug: Rescue medication

First Posted Date: 2010-11-19

Last Posted Date: 2024-06-20

Lead Sponsor: Organon and Co

Target Recruit Count: 404

Registration Number: NCT01244815

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Phase 1

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Ezetimibe/atorvastatin 10mg/80mg FDC
Drug: Ezetimibe/atorvastatin 10mg/10mg FDC
Drug: Ezetimibe
Drug: Atorvastatin 10mg
Drug: Atorvastatin 80mg

First Posted Date: 2010-11-07

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 200

Registration Number: NCT01236430

A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Etoricoxib 60 mg
Drug: Etoricoxib 90 mg
Drug: Placebo to Etoricoxib 60 mg
Drug: Placebo to Etoricoxib 90 mg

First Posted Date: 2010-09-23

Last Posted Date: 2024-06-18

Lead Sponsor: Organon and Co

Target Recruit Count: 1404

Registration Number: NCT01208181

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

Phase 3

Completed

Conditions: Spondylitis, Ankylosing

Interventions: Drug: Part I - etoricoxib 60 mg
Drug: Part I- naproxen 1000 mg
Drug: Part I - etoricoxib 90 mg
Drug: Part I - Placebo to naproxen 500 mg
Drug: Part II- naproxen 1000 mg
Drug: Part II- etoricoxib 60 mg
Drug: Part I - Placebo to etoricoxib 60 mg
Drug: Part II- etoricoxib 90 mg
Drug: Part I - Placebo to etoricoxib 90 mg
Drug: Part II - Placebo to etoricoxib 90 mg
Drug: Part II- Placebo to etoricoxib 60 mg
Drug: Part II- Placebo to naproxen 500 mg

First Posted Date: 2010-09-23

Last Posted Date: 2024-06-18

Lead Sponsor: Organon and Co

Target Recruit Count: 1015

Registration Number: NCT01208207

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

Phase 1

Completed

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: Asenapine 2.5 mg
Drug: Asenapine 5 mg
Drug: Asenapine 10 mg

First Posted Date: 2010-09-22

Last Posted Date: 2024-05-23

Lead Sponsor: Organon and Co

Target Recruit Count: 30

Registration Number: NCT01206517

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

Phase 3

Completed

Conditions: Schizophrenia, Paranoid
Schizophrenia, Disorganized
Schizophrenia, Undifferentiated

Interventions: Drug: asenapine

First Posted Date: 2010-08-27

Last Posted Date: 2024-05-22

Lead Sponsor: Organon and Co

Target Recruit Count: 204

Registration Number: NCT01190267

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)

Phase 3

Completed

Conditions: Schizophrenia, Disorganized
Schizophrenia, Paranoid
Schizophrenia, Undifferentiated

Interventions: Drug: placebo
Drug: asenapine 2.5 mg
Drug: asenapine 5.0 mg

First Posted Date: 2010-08-27

Last Posted Date: 2024-05-21

Lead Sponsor: Organon and Co

Target Recruit Count: 306

Registration Number: NCT01190254

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy